GlassScriptPhysician profile
Eli R Cianciolo
NPI 1013128305
$3,792.08
in general payments reported to CMS, 2019-2025
24 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $125 · 2021: $372 · 2022: $325 · 2023: $315 · 2024: $669 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,413.25 | 2019-2025 | Wavewriter Alpha Prime 16, Artisan, Entrada |
| Medtronic, INC. | $1,402.16 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Novartis Pharmaceuticals Corporation | $116.60 | 2019-2020 | |
| Bioventus LLC | $114.99 | 2019 | |
| Neurocrine Biosciences, INC. | $87.41 | 2023-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $81.78 | 2019-2025 | |
| Nevro Corp. | $69.65 | 2019 | |
| Amneal Pharmaceuticals LLC | $68.32 | 2022-2023 | Lyvispah |
| Teva Pharmaceuticals USA, INC. | $65.81 | 2019 | |
| Acadia Pharmaceuticals INC | $51.95 | 2019-2025 | Nuplazid |
| Abbvie INC. | $39.66 | 2024-2025 | |
| Lilly USA, LLC | $34.93 | 2019-2025 | Kisunla, Amyvid |
| Tanabe Pharma America, INC. | $28.64 | 2019 | |
| Abbott Laboratories | $27.87 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $27.46 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.20 | 2020 | |
| Grifols USA, LLC | $21.92 | 2019 | |
| Biogen, INC. | $21.61 | 2025 | Leqembi |
| Averitas Pharma INC. | $20.39 | 2023 | Qutenza |
| Sunovion Pharmaceuticals INC. | $20.32 | 2019 | |
| Tg Therapeutics, INC. | $15.96 | 2025 | |
| Kyowa Kirin, INC. | $13.66 | 2019 | |
| Pfizer INC. | $12.61 | 2019 | |
| Acorda Therapeutics, INC | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Cianciolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.